Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104852 · ClinicalTrials.gov registry record
Triage Survey for Neurology Research Eligibility
A clinical trial of Alzheimer Disease, sponsored by Adams Clinical.
- Recruiting
- Registry status
- 600
- Enrollment target
- 3
- Study locations
NCT06104852: Recruiting study of Alzheimer Disease, sponsored by Adams Clinical.
NCT06104852 is a study of Alzheimer Disease that is actively recruiting participants, run by Adams Clinical. The registered enrollment target is 600 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06104852, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Adams Clinical.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 3
- Study locations
Study Summary
TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Optional Medication Washout
Study Locations (3)
Massachusetts
- Copley Clinical - Boston
- Adams Clinical - Watertown
New York
- Berman Clinical - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2027-06-02 |
What NCT06104852 shows while recruiting
NCT06104852 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Survey is the first listed.
NCT06104852 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06104852 about?
NCT06104852 is a clinical study titled "Triage Survey for Neurology Research Eligibility". TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
What is the current status of trial NCT06104852?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2023-06-02. Estimated completion is 2027-06-02.
What conditions does trial NCT06104852 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06104852?
The interventions under investigation include: Survey (OTHER), Optional Medication Washout (OTHER).
Who is sponsoring clinical trial NCT06104852?
This trial is sponsored by Adams Clinical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104852 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06104852's enrollment target sits among peer trials
600 46th of 306 higher than 259 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI